Overview

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Bayer